European surgeon training announcement for GelrinC drives RGNT 137% premarket surge
- Regentis issued June 8 PR detailing Q3 2026 start of hands-on EU surgeon training for CE Mark-approved GelrinC hydrogel implant.
- Training begins at Humanitas Research Hospital in Milan; additional sessions and Centers of Excellence planned across Europe.
- News marks key step accelerating commercial launch preparations for off-the-shelf knee cartilage repair product.
- Low-float nano-cap stock (post-Dec 2025 IPO at $8, recent ~$1.28 close) reacted sharply to positive commercialization update.
- After-hours/premarket trading pushed shares from $1.28 close to ~$3.00–$3.30 range (+127–160%), with elevated volume.
- Builds on prior EU collaboration with Humanitas and manufacturing improvements; no other major catalyst identified.
- Retail momentum amplified move in this small-cap regenerative medicine name per forum and news coverage.
